Multi Donor Mismatched Stem Cell Transplantation (MDT)

Status Recruiting

Clinical Trial Summary

The proposed research focuses on the development of innovative protocol of mismatched stem cell transplantation with combined 2 different haplo stem cell transplantation (SCT) donors which are mismatched to the recipient (and preferably to each other), in a patient in need for SCT, lacking an HLA match related or an unrelated donor. This innovative protocol named multi donor stem cell transplantation (MDT) is designed to facilitate engraftment even when reduced intensity conditioning or a low cell dose are used, improve the graft vs. leukemia (GVL) effect and enhance immune reconstitution (using quantitative and qualitative parameters).

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00716690
Study type	Interventional
Source	Hadassah Medical Organization
Contact	Michael Y Shapira, MD
Phone	00 972 2 6778351
Email	shapiram@hadassah.org.il
Status	Recruiting
Phase	Phase 1/Phase 2
Start date	July 2008
Completion date	June 2020

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT01428973` - Minitransplants With HLA-matched Donors : Comparison Between 2 GVHD Prophylaxis Regimens	Phase 2
Not yet recruiting	`NCT00749164` - Allogeneic Mesenchymal Stem Cell for Graft-Versus-Host Disease Treatment	Phase 1/Phase 2
Completed	`NCT00993343` - Randomized Trial Comparing Sirolimus and Tacrolimus Versus Cyclosporine and Methotrexate as Graft-versus-host Disease (GVHD) Prophylaxis After Allogeneic Stem Cell Transplantation	Phase 3
Completed	`NCT00360685` - Tacrolimus and Mycophenolate Mofetil (MMF) in GVHD Prophylactic Regimen Compared to Tacrolimus and Methotrexate (MTX	N/A
Active, not recruiting	`NCT04503616` - Cyclophosphamide, Abatacept, and Tacrolimus for GvHD Prevention	Phase 1/Phase 2
Terminated	`NCT02080195` - Nonmyeloablative Conditioning and Transplantation for Patients With Refractory Systemic Lupus Erythematosus (SLE)	Phase 1/Phase 2
Completed	`NCT02193880` - Safety of Post-transplant Alpha-beta Depleted T-cell Infusion Following Haploidentical Stem Cell Transplant (Haplo SCT)	N/A
Completed	`NCT02942173` - CD45RA Depleted T-cell Infusion for Prevention of Infections After TCRab/CD19-depleted Allo-HSCT	Phase 2/Phase 3
Completed	`NCT02145403` - Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies	Phase 1/Phase 2
Recruiting	`NCT01941394` - Mesenchymal Stem Cells Infusion for aGVHD Prophylaxis Transplantation	Phase 2
Completed	`NCT00141713` - The Use of Etanercept (Enbrel®) in the Treatment of Acute Graft-Versus-Host Disease	Phase 2
Recruiting	`NCT01991301` - Carfilzomib for the Prevention of Graft Versus Host Disease	Phase 1
Completed	`NCT00408928` - Study on the Safety and Effectiveness of VELCADE® in the Treatment of Graft-Versus-Host Disease	Phase 2
Completed	`NCT01633229` - Bone Marrow Stromal Cell Infusions for Stem Cell Transplant Complications	Phase 1
Completed	`NCT05856058` - To Assess SHR0302 Oral Solutions and Tablets in Healthy Subjects Clinical Studies of Relative Bioavailability	Phase 1
Completed	`NCT02342613` - Adoptive Immunotherapy With Activated Marrow Infiltrating Lymphocytes and Cyclophosphamide Graft-Versus-Host Disease Prophylaxis in Patients With Relapse of Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation	Phase 1
Recruiting	`NCT06423131` - Prospective Clinical Trial for Children With TCRαβ Depleted vs Traditional Haplo Identicle HSCT	N/A
Completed	`NCT02144025` - Prevention of Ocular Graft-Versus-Host Disease With Topical Cyclosporine in Recipients of Allogeneic HSCT	Phase 2
Completed	`NCT01369914` - The Natural History of Graft-Versus-Host Disease in the Eyes
Completed	`NCT00806728` - Study of MEDI-507 in With Steroid-Resistant Acute Graft-Versus-Host Disease	Phase 1